Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor

Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing

Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care